Abstract
Background:
The object of this study was to investigate the clinical predictive capability of peripheral myeloid dendritic cells (DCs) in Wilms' tumor 1 (WT1) vaccine therapy for patients with gynaecological cancer.
Patients and methods:
Six patients with WT1/human leukocyte antigen (HLA)-A*2402-positive gynaecological cancer were included in this study. The patients received intradermal injections of a modified 9-mer WT1 peptide every week for 12 weeks. Peripheral blood samples were obtained at 0, 4, 8 and 12 weeks after the initial vaccination. Circulating DCs were detected by flow cytometry.
Results:
The frequencies of CD14(+)CD16(+)CD33(+)CD85(+) myeloid DCs were significantly higher in the therapeutically effective group than in therapeutically inert group (p<0.05).
Conclusion:
These results suggested that myeloid DCs, which should be associated with inducing cytotoxic T-cells, provided additional prognostic information in the use of cancer peptide vaccine.
Publication types
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic
-
Adult
-
Blood Cell Count*
-
Cancer Vaccines / immunology*
-
Combined Modality Therapy
-
Dendritic Cells*
-
Female
-
Flow Cytometry
-
Genital Neoplasms, Female / blood*
-
Genital Neoplasms, Female / drug therapy
-
Genital Neoplasms, Female / immunology
-
Genital Neoplasms, Female / surgery
-
Genital Neoplasms, Female / therapy
-
HLA-A Antigens / administration & dosage
-
HLA-A Antigens / immunology
-
HLA-A24 Antigen
-
Humans
-
Immunization Schedule
-
Immunologic Surveillance
-
Immunophenotyping
-
Immunotherapy, Active*
-
Injections, Intradermal
-
Middle Aged
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / immunology
-
Treatment Outcome
-
Tumor Burden
-
Vaccines, Subunit / immunology
-
WT1 Proteins / administration & dosage
-
WT1 Proteins / immunology*
Substances
-
Adjuvants, Immunologic
-
Cancer Vaccines
-
HLA-A Antigens
-
HLA-A*24:02 antigen
-
HLA-A24 Antigen
-
Peptide Fragments
-
Vaccines, Subunit
-
WT1 Proteins